SLSSELLAS Life Sciences Group, Inc.

1. Aug 11, 2026SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
2. Jul 27, 2026As previously disclosed, the Company commenced a binding arbitration against 3D Medicines, Inc. (“3D Medicines”), administered by the Hong Kong International Arbitration Centre (“HKIAC”)Earnings release · Form 8-K
3. Jun 25, 2026Compensatory Arrangements of Certain Officers On June 24, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) entered into (i) an amendment (the “Stergiou Amendment”) to that certain employment agreement effective as of July 1, 2019 (the “Stergiou Employment Agreement”), by and between the Company and Dr. Angelos …Director or officer change · Form 8-K
4. Jun 2, 2026As previously reported, as of March 31, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) had $107.1 million of cash and cash equivalents.Other event · Form 8-K
5. May 12, 2026SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
6. Mar 19, 2026SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
7. Mar 11, 2026As previously reported on January 8, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) received approximately $26.5 million in proceeds as of such date from the exercise of common stock warrants subsequent to December 31, 2025.Other event · Form 8-K
8. Jan 8, 2026Subsequent to December 31, 2025, the Company received approximately $26.5 million in proceeds from the exercise of common stock warrants. As of January 7, 2026, the Company had 170,282,026 shares of common stock outstanding.Earnings release · Form 8-K
9. Nov 12, 2025SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update.Earnings release · press release
10. Oct 27, 2025On October 24, 2025, SELLAS Life Sciences Group, Inc. a Delaware corporation (the “Company”), entered into a Warrant Inducement Agreement (the “Inducement Agreement”) with holders (the “Holders”) of certain existing warrants (the “Existing Warrants”) to purchase shares of common stock, par value $0.0001 per share (the …Material agreement entered · Form 8-K
11. Oct 3, 2025On October 1, 2025, SELLAS Life Sciences Group, Inc. (the “Company”), as subtenant, entered into a Letter Agreement with Times Square Tower Associates LLC (the “Sublandlord”) relating to a certain sublease (as amended) of certain premises located at Times Square Tower, 7 Times Square, New York, New York (the …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.